However, class I HDAC inhibitors have exhibited mixed results in different AKI models, which may result from differences in the time course of tubular repair among AKI models, the structures of administered HDAC inhibitors, and the dose and timing of administration [81]. The gene discussed is HDAC9; the disease is acute kidney injury.